Lisata Therapeutics Inc (LSTA) Stock Price, Quote & News

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens....

Industry: Biotechnology

Sector: Healthcare

Phone: 908 842 0100

Website: www.lisata.com

Address:

110 Allen Road, 2nd Floor, Basking Ridge, United States

skyrockets_Inc Aug. 19 at 3:07 PM

$LSTA Agreed w/ post below @Biotech_Pharma_Investor! As confirmed by Kuva CEO yesterday via email they are still actively working on putting together a fully funded offer. This option is not dead yet, but even if it is and RM is the solution, we are still in a safe zone imo. 10Q shows 10m cash end of June 30, 2026. 1.2m in costs with workforce reduction, and burn of 3-4m in GA expenses puts this at 5m cash end of Sept 30, 2026. Likely has 7m in cash today + NASDAQ shell worth 7-10m. In an RM scenario the likely value would be 3m cash + NASDAQ shell = 10m or 1.10/share FLOOR valuation, giving ZERO value to assets. The math still supports the current PPS imo If anyone needs convincing, take a look at $PCSA which had negative cash (weeks away from BK) and just completed a RM transaction and is trading at 6m mc. NASDAQ shells have a lot more value than people like to admit!

0 · Reply

skyrockets_Inc Aug. 18 at 6:57 PM

$LSTA Suspicious buying lately. Kuva CEO recently confirmed to me that they are still actively working on getting funding together for an updated offer to Lisata. Perhaps it's coming soon ???

0 · Reply

skyrockets_Inc Aug. 11 at 3:58 PM

$LSTA Exactly as I predicted in my post below. The lawsuit is leverage to get Kuva to complete the offer as is (or reduced). Both sides have confirmed to me via email they are still open to it and currently working on it. I emailed CEO two days ago and just double confirmed that the relationship is not soured because of the lawsuit. Here is his response: " The simple answer is “yes” to the openness to a “fully funded legitimate offer” from Kuva. The filing of the suit is to recoup damages to our shareholders for their breach of contract. It would seem that the simplest way for them to make the suit go away would be to complete the deal they offered. DJM "

0 · Reply

Biotech_Pharma_Investor Aug. 7 at 5:52 PM

$LSTA Kuva will either have to pay $2M (+ litigation) and get nth or find the cash and close the deal

1 · Reply

skyrockets_Inc Aug. 7 at 5:35 PM

$LSTA 10Q shows 10m cash end of June 30, 2026. 1.2m in costs with workforce reduction, and burn of 3-4m in GA expenses puts this at 5m cash end of Sept 30, 2026. Likely has 7m in cash today + NASDAQ shell worth 7-10m. In an RM scenario the likely value would be 3m cash + NASDAQ shell = 10m or 1.10/share FLOOR valuation, giving ZERO value to assets. The math still supports the current PPS imo

0 · Reply

majsterJoda Aug. 7 at 11:12 AM

$LSTA this should be priced below 50c

0 · Reply

majsterJoda Aug. 7 at 11:10 AM

$LSTA cash 8 mil - 70% workforce retention bonusess ... we can say 5 mil

1 · Reply

TwongStocks Aug. 6 at 8:20 PM

$LSTA 10-Q filed after hours today https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000032001726000038/lsta-20260630.htm • Cash is $10.44M as of June 30th. • They estimate that they will incur approximately $1.2 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.

0 · Reply

majsterJoda Aug. 6 at 12:12 PM

$LSTA they have less than 5mil cash this should fall soon

0 · Reply

skyrockets_Inc Aug. 4 at 5:36 PM

$LSTA PR today is in line w/ expectations of companies next steps. Proceed w/ litigation as discussed in previous filing, put pressure on Kuva (who is still actively working on funding) while proceeding w/ a secondary strategic alternative process likely looking for merger candidates. Option A). Kuva returns with FULLY FUNDED tender offer in 2.50-3.50/share range upfront --> LSTA accepts--> Stock pops--> Lawsuit dropped. Option B). Kuva does not return with offer, or returns with sub-par offer that LSTA rejects (i.e. $1/share range). --> Lawsuit proceeds --> LSTA finds RM candidate (5m in net cash + 5-7m in NASDAQ shell value puts deal value at $1.10/share MIN, w/ no value given to legacy assets). CFO is employed through Dec31 2026 so any deal will likely come months before then. Win-win solution either way imo.

0 · Reply

Lisata Therapeutics Quarterly report: Q2 2026

2026-08-04T13:20:45.000Z - 15 days ago

Market Cap	9.73M
Revenue (ttm)	170,000.00
Net Income (ttm)	-16.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9,758.82%
Debt to Equity Ratio	0.00

Volume	147,955
Avg Vol	92,232
Day's Range	N/A - N/A
Shares Out	9.01M
Stochastic %K	50%
Beta	0.88
Analysts	Hold
Price Target	$4.00